Library Subscription: Guest
Critical Reviews™ in Oncogenesis

Published 4 issues per year

ISSN Print: 0893-9675

ISSN Online: 2162-6448

SJR: 0.395 SNIP: 0.322 CiteScore™:: 2.5 H-Index: 54

Indexed in

Antisense Oligonucleotide Therapeutics for Human Leukemia

Volume 8, Issue 1, 1997, pp. 93-109
DOI: 10.1615/CritRevOncog.v8.i1.50
Get accessGet access

ABSTRACT

The development of reliable gene disruption strategies, and their application in living cells, has proven to be an extraordinarily important advance for cell and molecular biologists. Using the various available approaches, the specific functions of any given gene may now be investigated directly in the relevant cell type. Application of similar experimental tools in a clinical setting might prove to be equally valuable and could well form the basis of a monumental advance in the practice of clinical medicine. This seems particularly true at the present time since much progress has been made in understanding the molecular pathogenesis of many diseases, including cancer. For these reasons a tremendous amount of interest has been generated in the use of oligodeoxynucleotides to modify gene expression. However, in spite of some notable successes which are detailed in this review, oligonucleotides have generated controversy in regards to their mechanism of action, reliability, and ultimate therapeutic utility. Nevertheless, the potential power of the "antisense" approach remains undisputed, and its ultimate therapeutic utility is far reaching. Accordingly, the problems associated with the use of these compounds are clearly worth solving. It remains the hope of many laboratories that the day will soon come when these techniques will make an important contribution to the management of CML and other neoplastic disorders.

CITED BY
  1. VERFAILLIE CATHERINE M., ZHAO ROBERT CH, Gene Therapy for Chronic Myelogenous Leukemia, in Gene Therapy of Cancer, 2002. Crossref

  2. Williams Shirley A., Buzby Jeffrey S., Cell-specific optimization of phosphorothioate antisense oligodeoxynucleotide delivery by cationic lipids, in Antisense Technology Part A: General Methods, Methods of Delivery, and RNA Studies, 313, 2000. Crossref

  3. Ghosh Indraneel, Chmielewski Jean, A β-sheet peptide inhibitor of E47 dimerization and DNA binding, Chemistry & Biology, 5, 8, 1998. Crossref

  4. Jacobs R.M., Messick J.B., Valli V.E., Tumors of the Hemolymphatic System, in Tumors in Domestic Animals, 2008. Crossref

  5. Mechanism of Action and Metabolism of Antineoplastic and Chemopreventive Agents, in Mass Spectrometry in Cancer Research, 2002. Crossref

Begell Digital Portal Begell Digital Library eBooks Journals References & Proceedings Research Collections Prices and Subscription Policies Begell House Contact Us Language English 中文 Русский Português German French Spain